Cereno Scientific
4.036 SEK +0.15%2 investors are following this company
Cereno Scientific are active within biotechnology. Today, the company is focused on developing pharmaceuticals for the treatment of various cardiovascular diseases. The products are used to treat potential blood clots that may lead to stroke, myocardial infarction, pulmonary embolism, as well as venous thrombosis. The company was founded in 2012 and is based in Mölndal.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CRNO B
Daily low / high price
3.982 / 4.098
SEK
Market cap
1.14B SEK
Turnover
1.75M SEK
Volume
436K
Latest videos
Financial calendar
Interim report
2024-05-23
General meeting
2024-05-28
Interim report
2024-08-29
Interim report
2024-11-21
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 20.6 % | 20.1 % |
Pareto Securities AS | 3.2 % | 3.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Kommuniké från årsstämma 2024 i Cereno Scientific AB
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools